 NOVATO, Calif., Sept. 09, 2021 GLOBE NEWSWIRE -- Ultragenyx Pharmaceutical Inc., a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced that Mepsevii vestronidase alfa has been approved for reimbursement by the Agenzia Italiana del Farmaco Italian Medicines Agency AIFA for the treatment of pediatric and adult patients with Mucopolysaccharidosis VII MPS VII; Sly syndrome. 